Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review

Revista Do Instituto De Medicina Tropical De São Paulo
Marcos MucenicGuido Pio Cracco Cantisani

Abstract

Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment after liver transplantation. However, pegylated interferon may still be required for genotype 3 non-responders. We treated a liver graft recipient with grade 1 fibrosis in the biopsy with daclatasvir and sofosbuvir for 12 weeks. He did not respond and progressed to grade 3 fibrosis. Lacking other options, we obtained a sustained virological response with pegylated interferon, ribavirin and sofosbuvir for 12 weeks. The combination of pegylated interferon, ribavirin and sofosbuvir is a viable option after the failure of direct acting antivirals in economically disadvantaged countries.

References

Feb 6, 2004·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Manal F AbdelmalekDavid R Nelson
Jul 6, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Thierry BizollonChristian Trepo
Aug 30, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·B J VeldtM R Charlton
Aug 12, 2009·Journal of Hepatology·Pierre-Yves BochudUNKNOWN Swiss Hepatitis C Cohort Study Group
Jul 7, 2014·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Adriano M PellicelliMario Angelico
Aug 26, 2014·World Journal of Gastroenterology : WJG·Andrew S deLemosMark W Russo
Nov 12, 2014·The New England Journal of Medicine·Paul Y KwoXavier Forns
Feb 28, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Surakit PungpapongAndrew P Keaveny
Apr 26, 2015·Journal of Hepatology·UNKNOWN European Association for Study of Liver
Jun 26, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·UNKNOWN AASLD/IDSA HCV Guidance Panel
Jun 6, 2016·Journal of Hepatology·Audrey CoillyUNKNOWN ANRS C023 CUPILT study group
Jun 22, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jordan J FeldMichael W Fried
Mar 23, 2017·Journal of Hepatology·Luca S BelliMario Strazzabosco
Jun 1, 2017·The New England Journal of Medicine·Marc BourlièreUNKNOWN POLARIS-1 and POLARIS-4 Investigators
Apr 14, 2018·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver

❮ Previous
Next ❯

Citations

May 15, 2020·Clinical Microbiology Reviews·Naveen KumarBarry T Rouse
May 1, 2021·Viruses·Robert J GeraghtyLaurent F Bonnac

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies

Software Mentioned

TARGET

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.